Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04042480 · ClinicalTrials.gov registry record · Phase 1
A Study of SGN-CD228A in Advanced Solid Tumors
A Phase 1 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT04042480: Clinical Trial Phase 1 study, sponsored by Seagen.
NCT04042480 is a Phase 1 study that was terminated before completion, run by Seagen. The registered enrollment target is 88 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04042480, a Phase 1 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
This trial will study SGN-CD228A to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. The study will have two parts. Part 1 of the study will find out how much SGN-CD228A should be given for treatment and how often. Part 2 of the study will use the dose found in Part 1 and look at how safe and effective the treatment is.
Primary Outcome
Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
Interventions
- DRUG SGN-CD228A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2019-09-03 |
| Est. Completion | 2023-03-09 |
| Phase | Phase 1 |
Why NCT04042480 stopped before completion
NCT04042480 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% higher).
The record links to 0 conditions, and to 1 intervention - of which SGN-CD228A is the first listed.
NCT04042480 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04042480 about?
NCT04042480 is a clinical study titled "A Study of SGN-CD228A in Advanced Solid Tumors". This trial will study SGN-CD228A to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. The study will have two parts. Part 1 of the study will find out how much SGN-CD228A should be given for treatment and...
What is the current status of trial NCT04042480?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2019-09-03. Estimated completion is 2023-03-09.
What interventions are being tested in trial NCT04042480?
The interventions under investigation include: SGN-CD228A (DRUG).
Who is sponsoring clinical trial NCT04042480?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04042480's enrollment target sits among peer trials
88 650th of 2000 higher than 1,350 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI